KAI Pharmaceuticals

Pionyr Immunotherapeutics Inc. is part of a huge second wave of companies looking to take immuno-oncology to the next level – changing the tumor microenvironment to overcome limitations of the leadin

Merck Sharp & Dohme Ltd. 's PD-1-targeting antibody Keytruda (pembrolizumab) has been added to the reimbursement list and launched in Japan for non-small cell lung cancer (NSCLC), and will provide

Merck Sharp & Dohme Ltd. 's ( Merck & Co. Inc. ) Keytruda (pembrolizumab) has received approval in Japan for the additional major indication of non-small cell lung cancer (NSCLC), and looks likel

Amgen Inc. ’s Sensipar (cinacalcet) follow-on Parsabiv (etelcalcetide) appeared poised for a smooth regulatory review with a data package made up of three Phase III clinical trials, including a h